期刊
JOURNAL OF CROHNS & COLITIS
卷 15, 期 2, 页码 171-194出版社
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjaa161
关键词
Practice guideline; Crohn's disease/therapy; child; algorithms
资金
- European Crohn's and Colitis Organisation
- European Society for Paediatric Gastroenterology Hepatology and Nutrition
This study emphasizes the importance of early assessment of high-risk patients with Crohn's disease to reduce intestinal damage, and recommends upfront anti-TNF agents in combination with an immunomodulator for patients with perianal disease, stricturing or penetrating behavior, or severe growth retardation. Therapeutic drug monitoring is preferred over empirically escalating anti-TNF dose or switching therapies. For low-risk luminal CD patients, induction with exclusive enteral nutrition or corticosteroids, and maintenance therapy with immunomodulators are recommended.
Objective: We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn's disease [CD]. Methods: We formed 10 working groups and formulated 17 PICO-structured clinical questions [Patients, Intervention, Comparator, and Outcome]. A systematic literature search from January 1, 1991 to March 19, 2019 was conducted by a medical librarian using MEDLINE, EMBASE, and Cochrane Central databases. A shortlist of 30 provisional statements were further refined during a consensus meeting in Barcelona in October 2019 and subjected to a vote. In total 22 statements reached >= 80% agreement and were retained. Results: We established that it was key to identify patients at high risk of a complicated disease course at the earliest opportunity, to reduce bowel damage. Patients with perianal disease, stricturing or penetrating behaviour, or severe growth retardation should be considered for up-front anti-tumour necrosis factor [TNF] agents in combination with an immunomodulator. Therapeutic drug monitoring to guide treatment changes is recommended over empirically escalating anti-TNF dose or switching therapies. Patients with low-risk luminal CD should be induced with exclusive enteral nutrition [EEN], or with corticosteroids when EEN is not an option, and require immunomodulator-based maintenance therapy. Favourable outcomes rely on close monitoring of treatment response, with timely adjustments in therapy when treatment targets are not met. Serial faecal calprotectin measurements or small bowel imaging [ultrasound or magnetic resonance enterography] are more reliable markers of treatment response than clinical scores alone. Conclusions: We present state-of-the-art guidance on the medical treatment and long-term management of children and adolescents with CD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据